Welcome to Arana Therapeutics

• Completed the divestment of non-core assets to fully focus on next generation antibodies
• Successfully completed the merger with EvoGenix to further enhance antibody engineering technologies and broaden our product pipeline
• Filed our first Investigational New Drug application (IND) for ART621 in rheumatoid arthritis
• Progressed ART621, our lead anti-inflammatory product, into Phase II clinical trials
• Established new commercial partnerships, including the agreement with Kyowa Hakko Kirin (KHK) to co-develop ART104 and a technology collaboration with Greenovation
• Selected a lead antibody candidate and commenced initial stage of manufacturing for ART010
• Achieved project milestones and success-based payments from progress under technology platform agreements with GSK, CSL and Vegenics
• Strengthened our balance sheet and sustained recurring revenues through international licensing and commercialisation deals - cash reserves of $181.6 million

Looking forward - upcoming clinical milestones are...

• Results for the psoriasis Phase II trial for ART621 to be released in early 2009
• A Phase II rheumatoid arthritis (RA) trial for ART621 planned to commence in the fourth quarter 2008
• A Phase I trial for bone cancer molecule ART010 projected to start in the first quarter 2010
• Commence a Phase I/II trial in age-related macular degeneration (AMD) with PMX53 in the first half of 2009